Corporate
Novo Nordisk Slashes Wegovy and Ozempic Prices by Up to 50%—One Day After CagriSema Trial Failure
3d ago
You're signed outSign in or to get full access.
NOVO NORDISK A S (NVO) Earnings Call Transcripts
Browse quarterly earnings call transcripts for NOVO NORDISK A S.
Q4 2025
Feb 5, 2026
Q4 2025
Feb 4, 2026
Q3 2025
Nov 5, 2025
Q2 2025
Aug 7, 2025
Q2 2025
Aug 6, 2025
Q1 2025
May 7, 2025
Q4 2024
Feb 5, 2025
Q3 2024
Nov 7, 2024
Q3 2024
Nov 6, 2024
Q2 2024
Aug 8, 2024
Q2 2024
Aug 7, 2024
Q1 2024
May 3, 2024
Q1 2024
May 2, 2024
Q4 2023
Feb 1, 2024
Q4 2023
Jan 31, 2024
Recent News about NOVO NORDISK A S
Corporate
Novo Nordisk's CagriSema Loses to Eli Lilly's Zepbound in Head-to-Head Trial, Stock Hits 5-Year Low
4d ago
Corporate
Novo Nordisk's CagriSema Fails to Match Eli Lilly's Zepbound in Head-to-Head REDEFINE 4 Trial
4d ago
Corporate
Novo Nordisk Sues Hims & Hers for Patent Infringement as FDA Cracks Down on GLP-1 Compounders
Feb 9
Corporate
Novo Nordisk Warns of Sales Decline in 2026—Stock Plunges 12%
Feb 3
Corporate
Novo Nordisk Cuts Wegovy Prices 50% in China as Patent Cliff Looms
Dec 29, 2025